Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data which demonstrated only mediocre efficacy for two of its therapies for breast and lung cancer.
Original Article: Roche's breast, lung cancer offerings fail to impress at ASCO